Differenzialindikation von Antidepressiva

S. Köhler; A. Arndt; P. Sterzer; T. Bschor

doi:10.1055/s-0032-1330403

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2013; 81(2): 104-118
DOI: 10.1055/s-0032-1330403

Fort- und Weiterbildung

Differenzialindikation von Antidepressiva

Individualized Treatment with Antidepressants

S. Köhler

¹Klinik für Psychiatrie und Psychotherapie, Charité, Berlin

,

A. Arndt

¹Klinik für Psychiatrie und Psychotherapie, Charité, Berlin

,

P. Sterzer

¹Klinik für Psychiatrie und Psychotherapie, Charité, Berlin

,

T. Bschor

²Klinik für Psychiatrie, Schlosspark-Klinik, Berlin

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?. J Clin Epidemiol 2001; 54: 541-549
2 DGPPN, BÄK, KBV et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. 23.09.2010 cited 2009 Available from: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de
3 Härter M, Klesse C, Bermejo I et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int 2010; 107: 700-708
4 Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
5 Turner E, Moreno SG, Sutton AJ. Ranking antidepressants. Lancet 2009; 373: 1760 ; author reply 1761–1762
6 Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005; 66: 1409-1414
7 Benkert O, Hippius H. Antidepressiva, in Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer; 2011: 1-132
8 Lotufo-Neto F, Bernik M, Ramos RT et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001; 15: 13-17
9 Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry 2003; 15: 171-180
10 Davidson JR, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013
11 Albert U, Aguglia E, Maina G et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63: 1004-1009
12 Bloch MH, McGuire J, Landeros-Weisenberger A et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010; 15: 850-855
13 Bisson JI. Post-traumatic stress disorder. Clin Evid 2010; (Online)
14 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; 4: CD007115
15 Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454
16 Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 71: 754-763
17 O’Brien S, Rapkin A, Dennerstein L et al. Diagnosis and management of premenstrual disorders. BMJ 2011; 342: d2994
18 Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011; 25: 371-382
19 Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167
20 Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006; 8: 478-488
21 Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320
22 Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108: 687-693
23 Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma (1) receptor ligands. Curr Neuropharmacol 2008; 6: 344-366
24 Sadock BJ, Sadock VA. Behavioral Sciences/Clinical Psychiatry. In: Kaplan and Sadock’s Synopsis of Psychiatry. Philadelphia: Lippincott Williams and Wilkins; 2007: 977-1126
25 Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008; 9: 787-794
26 Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272
27 Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 2009; 10: 2145-2159
28 Bellani M, Dusi N, Yeh PH et al. The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1544-1552
29 Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-475
30 Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006; 26: 250-258
31 Müller N, Schennach R, Riedel M et al. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008; 8: 527-536
32 Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12: 1623-1632
33 Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68: 653-689
34 Javelot T, Javelot H, Baratta A et al. Acute psychotic disorders related to bupropion: review of the literature. Encephale 2010; 36: 461-471
35 Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 (Suppl. 01) 5-17
36 Hewett K, Gee MD, Krishen A et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010; 24: 1209-1216
37 Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011; epub ahead of print
38 De Berardis D, Di Iorio G, Acciavatti T et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10: 119-132
39 Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36
40 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
41 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870
42 Ben-Arie O, George GC. A case of tranylcypromine (“Parnate”) addiction. Br J Psychiatry 1979; 135: 273-274
43 Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-494
44 Köhler S, Bauer M, Adli M. Behandlungsstrategien der therapieresistenten Depression. Psychiatrie und Psychotherapie up2date 2012; 6: 137-148
45 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
46 Köhler S. Vergleich medikamentöser Behandlungsstrategien bei Patienten mit unipolarer Depression und primärem Therapieversagen in einem stationären Setting. Dresden: Medizinische Fakultät der Technischen Universität Carl Gustav Carus; 2011: 150
47 Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-179
48 Souery D, Serretti A, Calati R et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry 2011; 12: 364-375
49 Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19: 457-465
50 Blier P, Ward HE, Tremblay P et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-288
51 Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252
52 Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689-701